Immune checkpoint inhibitors ( ICIs ) have completely changed how advanced melanoma ( AM ) is managed. Patients with co-existing malignancies are not included in the data on ICI effectiveness because it has largely been limited to clinical trials. The most common type of adult leukemia is chronic lymphocytic lung cancer( CLL ), which is linked to a higher risk of developing melanoma. Systemic immunity is altered by CLL, which can lead to T-cell exhaustion and may reduce the effectiveness of ICI in patients who have the condition. Therefore, we set out to investigate the effectiveness of ICI in patients who also had these diagnoses.